Pharmaceutical compositions suitable for long-term storage at room temperature are described. The pharmaceutical composition comprises the compound of formula (I) and can be used for the treatment of steatohepatitis. Also described are methods for preparing the pharmaceutical composition and methods of treatment using the pharmaceutical compositions.

A method for improving mild cognitive impairment of a human patient includes providing a dose of 250 mg-500 mg of a composition once or twice a day for three months or more. The human patient has mild cognitive impairment with a score of 23 points or more and less than 27 points in the Mini-Mental State Examination, a score of 0.5 in the Clinical Dementia Rating, or a score of less than 25 points in the Montreal Cognitive Assessment. The composition includes imidazole dipeptide separated and purified from chicken extract or salmon extract. The imidazole dipeptide does not contain creatinine, and 75% or more of the imidazole dipeptide in the composition is anserine.

Provided is a pharmaceutical composition for orally administering a pharmaceutical active ingredient which has a pH-dependent solubility profile, said pharmaceutical composition making it possible to achieve excellent scrubbing efficiency regardless of the pH inside the alimentary canal. Said oral pharmaceutical composition contains a pharmaceutical active ingredient which has a pH-dependent solubility profile, an inorganic or organic acid, and a hydrophilic polymer.

The invention relates to brassinosteroid-derived cholestane derivatives, their use in the protection of cell damage, injury and cell death and compositions containing these derivatives. New generation of compounds possess also selective antineurodegenerative properties on neuronal cells and tissues and can be particularly used in the treatment and prophylaxis of neurodegenerative disease, particularly in the treatment and prophylaxis of Parkinson's disease.

The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

The present invention provides formulations comprising polypeptides and hydroxypropyl methylcellulose acetate succinate (HPMCAS) derivatives. The formulations are stable; for example, during high temperature processing and in possible low pH environments. In addition, the HPMCAS derivatives provide protection to a pH sensitive protein against acidic degradation products from aqueous hydrolysis of poly(lactic-co-glycolic acid) (PLGA) in PLGA-based delivery systems.

The present invention provides nanoparticles which contain a poorly water-soluble drug for treating hepatitis, and a method of producing the nanoparticles. More particularly, the present invention provides a method of producing nanoparticles for treating hepatitis, which includes: a first step of preparing a precursor mixture solution for synthesis of nanoparticles which include a drug for treating hepatitis; a second step of extracting the compound under supercritical or subcritical conditions; and a third step of dispersing the same, as well as the nanoparticles including a poorly water-soluble drug for treating hepatitis with improved bioavailability and without organic solvent residue.

The present disclosure provides a crystal form comprising a compound of Formula (I) and fumaric acid, wherein the crystal form satisfies at least one of the following conditions: (1) a particle size D.sub.90 of the active pharmaceutical ingredient ranges from about 5 μm to about 60 μm; and (2) a particle size D.sub.50 of the active pharmaceutical ingredient does not exceed about 30 μm; a pharmaceutical composition containing the crystal form, and a method for treating coronavirus-induced diseases by using the crystal form. The crystal form of the present disclosure enables the pharmaceutical composition containing the crystal form to have advantages such as a higher dissolution rate, a higher dissolution, and the like.

##STR00001##

Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.

The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon.